Pfizer generated free cash flow of $10.4 billion in the 12 months ending Sept. 30, 2025. During this period, the pharma giant ...

Pfizer (PFE) stock has attracted fresh attention after recent trading left its one-month return at a 3.3% decline and its ...

It's quite possible for the new year to fulfill this ambitious name. Investing $122,100 in these three high-yield dividend ...

Pfizer's 2026 revenue midpoint of $61B and EPS midpoint of $2.90 decline YoY, reflecting persisting headwinds. Read more on ...

With activist investors gone and revenue stabilizing, the undervalued pharmaceutical giant offers a compelling chance for ...

Both companies have faced some headwinds recently, but the core businesses and dividend payouts remain strong. Blackstone is ...

Now, it’s worth noting Stock Advisor’s total average return is 966 % — a market-crushing outperformance compared to 194% for ...

A high-yielding payout hasn't been enough reason for investors to buy Pfizer's stock. The pharmaceutical giant's valuation has been cut in half in just three years. Investors appear to be worried ...

Pfizer ( PFE +0.24%) pays a dividend that yields around 6.8%. While the yield has been pushed higher as share prices have ...

Pfizer reported third-quarter earnings this week that were generally underwhelming. The drugmaker announced that its sales sagged 2.2% to $12.36 billion and its adjusted EPS fell similarly by 2% year ...

Pfizer Inc. (NYSE:PFE) will release earnings results for the third quarter before the opening bell on Tuesday, Nov. 4. Analysts expect the health care company to report quarterly earnings at 64 cents ...

Pfizer enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution. Click here to read ...